Table E1.
Neoadjuvant and adjuvant therapy
| Therapy | Neoadjuvant therapy∗ | Adjuvant therapy† |
|---|---|---|
| Overall cohort (N = 2660) | ||
| Chemotherapy alone | 191 (73) | 270 (54) |
| Chemoradiation | 21 (8) | 95 (19) |
| Radiation alone | 0 | 88 (17) |
| Targeted therapy alone | 14 (5) | 36 (7) |
| Chemotherapy and targeted therapy | 5 (2) | 2 (0.4) |
| Targeted therapy and radiation | 0 | 5 (1) |
| Immunotherapy alone | 24 (9) | 3 (0.6) |
| Chemotherapy and immunotherapy | 5 (2) | 3 (0.6) |
| Immunotherapy and radiation | 0 | 1 (0.2) |
| Patients who developed brain metastasis (N = 206) | ||
| Chemotherapy alone | 56 (76) | 44 (44) |
| Chemoradiation | 8 (11) | 16 (16) |
| Radiation alone | 0 | 31 (31) |
| Targeted therapy alone | 4 (5) | 5 (5) |
| Chemotherapy and targeted therapy | 4 (5) | 0 |
| Targeted therapy and radiation | 0 | 2 (2) |
| Immunotherapy alone | 2 (3) | 1 (1) |
∗
N = 260 for the overall cohort; N = 74 for patients who developed brain metastasis.
†
N = 503 for the overall cohort; N = 99 for patients who developed brain metastasis.